Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.

Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?

But sasanlimab's use looks set to remain narrow.

The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.

Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.

In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.

At least 15 dual-payload ADCs will be discussed.

Ikena, Senti and others look to clinical presentations at AACR.

On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.